Last reviewed · How we verify
Topotecan and VP16 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Topotecan and VP16 (Topotecan and VP16) — New Mexico Cancer Research Alliance.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Topotecan and VP16 TARGET | Topotecan and VP16 | New Mexico Cancer Research Alliance | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Topotecan and VP16 CI watch — RSS
- Topotecan and VP16 CI watch — Atom
- Topotecan and VP16 CI watch — JSON
- Topotecan and VP16 alone — RSS
Cite this brief
Drug Landscape (2026). Topotecan and VP16 — Competitive Intelligence Brief. https://druglandscape.com/ci/topotecan-and-vp16. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab